USANA Health Sciences Inc. (USNA) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, USNA scores 50 out of 100, a letter grade of D, labeled "Roarable Sell — Underperform / Distribution Warning." The five pillars are: Fundamental Cash Engine 12/20 (ROIC 7.9%; FCF yield 3.22%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 13/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 5/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 14/20 (Altman Z 3.56; Piotroski F 7/9; Debt/Equity 0.5).

For a prospective investor, the pattern is a company with a sound balance sheet and moderate cash generation that is being scored down on institutional flow and macro/sector sensitivity. The strongest pillar is the forensic balance sheet; the weakest is macro regime fit, where a beta of 1.0 matches the market but the sector sensitivity assessment is low. The whale-flow pillar at 6/20 indicates weak institutional accumulation signals. Upside drivers would need to come from improved cash conversion and institutional re-accumulation; the valuation tradeoff is that the stock trades at a P/E (TTM) of 24.6 against a much lower EV/EBITDA of 2.7, a divergence an investor should reconcile against the reported earnings trend below. This is educational analysis, not personalized advice.

USANA Health Sciences Inc. is a NYSE-listed issuer in the Health Care sector, within the Medicinal Chemicals and Botanical Products industry. Per the Profile, the company operates in this industry with a market capitalization of $0.3B. Source data does not describe its specific products, customers, or revenue model beyond the sector and industry classification.

Per the SEC financials, revenue moved from $921.0M (FY 2023) to $854.5M (FY 2024) before recovering to $925.3M (FY 2025), while net income declined from $63.8M to $10.8M across the same span. Current market data shows a gross margin of 78.3%, an operating margin of 4%, and a net margin of 1.2%, with ROIC at 7.9%. Per the Roarable RQD rating, the Altman Z-Score is 3.56, the Piotroski F-Score is 7/9, and Debt/Equity is 0.5, indicating a balance sheet the rating treats as a relative strength.

Per the recent news section, the wire contains six items, all tied to USNA. Catalysts flagged include an upcoming quarterly earnings release (reported as a preview of Q3 results and a Tuesday release date), a Zacks rating change from strong sell to hold, and a price-action commentary piece. Five items carry a YELLOW light and one carries a GREEN light, the latter being the Zacks upgrade. Risk watch items are limited to the earnings event itself, since the wire contains no detailed financial disclosures. Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.

• What are the specific product lines and customer channels behind the $925.3M FY 2025 revenue?
• What drove the drop in net income from $63.8M (FY 2023) to $10.8M (FY 2025), and is it cyclical or structural?
• What is the EPS and debt figure behind the reported Debt/Equity of 0.5, given EPS and Debt are missing from the financial table?
• Why does a P/E of 24.6 coexist with an EV/EBITDA of 2.7, and which earnings base is the source using?
• What do the upcoming quarterly results need to show to shift the whale-flow and insider-conviction pillars?